Skip to content
2000
image of Unveiling the Role of DPYS: A New Prognostic Biomarker in Sarcoma

Abstract

Background

Dihydropyrimidinase (DPYS), a pivotal enzyme in the pyrimidine synthesis pathway, has been increasingly studied for its potential role in cancer therapy. While its presence has been noted in various cancers, its specific impact on sarcoma (SARC) still needs to be fully understood.

Objective

This study sought to explore the correlation between DPYS expression and SARC, utilizing data from The Cancer Genome Atlas (TCGA), bioinformatics tools, and experimental validation.

Methods

The study employed statistical analysis and logistic regression to assess the link between DPYS expression levels and clinical features in SARC patients. Survival analysis was conducted using the Kaplan-Meier method and Cox regression, evaluating the prognostic significance of DPYS expression. Gene set enrichment analysis and immuno-infiltration analysis were conducted to uncover the potential regulatory mechanisms of the DPYS gene. We validated the expression of DPYS using GSE17674. Quantitative reverse transcription PCR was utilized to measure DPYS expression levels in SARC cell lines.

Results

The study found that reduced DPYS expression in SARC correlated with therapeutic response ( 0.011), histological subtype ( 0.003), and the presence of residual tumor ( 0.043). Reduced DPYS expression was a predictor of inferior Overall Survival (OS), with a Hazard Ratio (HR) of 0.56 and a 95% Confidence Interval (CI) of 0.37-0.84 ( 0.005), as well as Disease-Specific Survival (DSS), with an HR of 0.64 and a 95% CI of 0.41-1.00 ( 0.048). DPYS expression was also identified as an independent factor for OS in SARC (HR: 0.335; 95% CI: 0.169-0.664; 0.002). The gene was associated with various pathways, including GPCR ligand binding, signaling by interleukins, G alpha (i) signaling events, Class A/1 Rhodopsin-like receptors, cytokine-cytokine receptor interaction, and platelet activation. DPYS expression also showed a correlation with certain immune cell infiltrates and was found to be significantly downregulated in SARC cell lines.

Conclusion

DPYS may serve as a potential prognostic biomarker and therapeutic target for SARC.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpps/10.2174/0113892037362065250227064739
2025-04-04
2025-09-10

  • From This Site

    /content/journals/cpps/10.2174/0113892037362065250227064739
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Kohlmeyer J.L. Gordon D.J. Tanas M.R. Monga V. Dodd R.D. Quelle D.E. CDKs in sarcoma: Mediators of disease and emerging therapeutic targets. Int. J. Mol. Sci. 2020 21 8 3018 10.3390/ijms21083018 32344731
    [Google Scholar]
  2. Bleloch J.S. Ballim R.D. Kimani S. Parkes J. Panieri E. Willmer T. Prince S. Managing sarcoma: Where have we come from and where are we going? Ther. Adv. Med. Oncol. 2017 9 10 637 659 10.1177/1758834017728927 28974986
    [Google Scholar]
  3. Potter J.W. Jones K.B. Barrott J.J. Sarcoma: The standard-bearer in cancer discovery. Crit. Rev. Oncol. Hematol. 2018 126 1 5 10.1016/j.critrevonc.2018.03.007 29759550
    [Google Scholar]
  4. Dancsok A.R. Asleh-Aburaya K. Nielsen T.O. Advances in sarcoma diagnostics and treatment. Oncotarget 2017 8 4 7068 7093 10.18632/oncotarget.12548 27732970
    [Google Scholar]
  5. Lin H. Ma Y. Wei Y. Shang H. Genome-wide analysis of aberrant gene expression and methylation profiles reveals susceptibility genes and underlying mechanism of cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016 207 147 152 10.1016/j.ejogrb.2016.10.017 27863272
    [Google Scholar]
  6. Chung W. Kwabi-Addo B. Ittmann M. Jelinek J. Shen L. Yu Y. Issa J.P.J. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 2008 3 4 e2079 10.1371/journal.pone.0002079 18446232
    [Google Scholar]
  7. Tahara T. Maegawa S. Chung W. Garriga J. Jelinek J. Estécio M.R.H. Shibata T. Hirata I. Arisawa T. Issa J.P.J. Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer Prev. Res. (Phila.) 2013 6 10 1093 1100 10.1158/1940‑6207.CAPR‑13‑0034 23943784
    [Google Scholar]
  8. Vasiljević N. Scibior-Bentkowska D. Brentnall A.R. Cuzick J. Lorincz A.T. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol. Oncol. 2014 132 3 709 714 10.1016/j.ygyno.2014.02.001 24508839
    [Google Scholar]
  9. Li S. Yang R. Sun X. Miao S. Lu T. Wang Y. Wo Y. Jiao W. Identification of SPP1 as a promising biomarker to predict clinical outcome of lung adenocarcinoma individuals. Gene 2018 679 398 404 10.1016/j.gene.2018.09.030 30240883
    [Google Scholar]
  10. Shen Y. Liu J. Zhang L. Dong S. Zhang J. Liu Y. Zhou H. Dong W. Identification of potential biomarkers and survival analysis for head and neck squamous cell carcinoma using bioinformatics strategy: A study based on TCGA and GEO datasets. BioMed Res. Int. 2019 2019 1 14 10.1155/2019/7376034 31485443
    [Google Scholar]
  11. Zou Y. Lin J. Liu J. Zhang F. Yang T. Gong J. Jiang T. Zuo J. Song R. Shen H. Shen F. Li J. Aspartate β-hydroxylase (ASPH) accelerates intrahepatic cholangiocarcinoma metastasis via upregulating SHH signaling pathway. Curr. Protein Pept. Sci. 2023 24 5 436 446 10.2174/1389203724666230502110404 37132101
    [Google Scholar]
  12. Yan J. Chen G. Dysregulation of SNHG16(lncRNA)-Hsa-Let-7b-5p(miRNA)-TUBB4A (mRNA) pathway fuels progression of skin cutaneous melanoma. Curr. Protein Pept. Sci. 2022 23 11 791 809 10.2174/1389201023666220928120902 36173063
    [Google Scholar]
  13. Liang K. Xie R. Xie Z. Wan W. Fu X. Lai X. Li D. Miao H. MEF2C is a potential prognostic biomarker and is correlated with immune infiltrates in lung adenocarcinoma. Curr. Med. Chem. 2024 32 10.2174/0109298673317910241003101925 39428936
    [Google Scholar]
  14. Pourghasem N. Ghorbanzadeh S. Nejatizadeh A. Expression and regulatory roles of small nucleolar RNA host gene 4 in gastric cancer. Curr. Protein Pept. Sci. 2023 24 9 767 779 10.2174/1389203724666230810094548 37565552
    [Google Scholar]
  15. Wang S. Zhang L. Li D. Gou M. Comprehensive analysis and experimental validation of HEPACAM2 as a potential prognosis biomarker and immunotherapy target in colorectal cancer. Curr. Gene Ther. 2024 25 10.2174/0115665232325395241018103006 39492767
    [Google Scholar]
  16. Wang X. Yan G. Zhang X. Li D. Li G. LNX1-AS2 as a key prognostic and immunotherapy response biomarker for lung adenocarcinoma. Curr. Med. Chem. 2024 32 10.2174/0109298673321029241015153958 39484773
    [Google Scholar]
  17. Xing S. Li D. Zhao Q. RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway. Aging (Albany NY) 2024 16 17 12392 12413 10.18632/aging.206096 39207452
    [Google Scholar]
  18. Jiang J. Du Z. Tang H. Huang Y. Li D. Liang Q. >Comprehensive analysis and experimental validation of TLL2 as a potential new prognostic biomarker associated with immune infiltration in lung adenocarcinoma Recent. Pat. Anticancer. Drug. Discov. 2024 Epub ahead of print.
    [Google Scholar]
  19. Qin H. Qi T. Xu J. Wang T. Zeng H. Yang J. Yu F. Integration of ubiquitination-related genes in predictive signatures for prognosis and immunotherapy response in sarcoma. Front. Oncol. 2024 14 1446522 10.3389/fonc.2024.1446522 39469643
    [Google Scholar]
  20. Wu Z. Tan J. Zhuang Y. Zhong M. Xiong Y. Ma J. Yang Y. Gao Z. Zhao J. Ye Z. Zhou H. Zhu Y. Lu H. Hong X. Identification of crucial genes of pyrimidine metabolism as biomarkers for gastric cancer prognosis. Cancer Cell Int. 2021 21 1 668 10.1186/s12935‑021‑02385‑x 34906153
    [Google Scholar]
  21. Wei X. Liu Y. Li W. Shao X. Nucleotide-binding oligomerization domain-containing protein 1 regulates inflammatory response in endometriosis. Curr. Protein Pept. Sci. 2022 23 2 121 128 35319362
    [Google Scholar]
  22. Yang H. Yu G. Wang Y. Guo X. REST-restrained lncRNA EPB41L4A-AS2 modulates laryngeal squamous cell carcinoma development via regulating miR-1254/HIPK2 pathway. Curr. Protein Pept. Sci. 2023 24 9 737 757 10.2174/1389203724666230803094028 37534482
    [Google Scholar]
  23. Cai F. Xu H. Song S. Wang G. Zhang Y. Qian J. Xu L. Knockdown of ubiquitin-conjugating enzyme E2 T abolishes the progression of head and neck squamous cell carcinoma by inhibiting NF-Κb signaling and inducing ferroptosis. Curr. Protein Pept. Sci. 2024 25 7 577 585 10.2174/0113892037287640240322084946 38584528
    [Google Scholar]
  24. Peivandi Z. Shirazi F.H. Teimourian S. Farnam G. Babaei V. Mehrparvar N. Koohsari N. Ashtarinezhad A. Silica nanoparticles-induced cytotoxicity and genotoxicity in A549 cell lines. Sci. Rep. 2024 14 1 14484 10.1038/s41598‑024‑65333‑5 38914713
    [Google Scholar]
  25. Ali S. Latif T. Sheikh M.A. Perveen S. Bilal M. Sarwar A. Testicular tumours in children: A single-centre experience. Singapore Med. J. 2023 Epub ahead of print. 10.4103/singaporemedj.SMJ‑2021‑380 37721303
    [Google Scholar]
  26. Capasso L. Florio M. Lillo M. Basilico M. De Santis V. Ziranu A. Grasso A. Minutillo F. Maccauro G. Vascular endothelial growth factor expression as a biomarker of prognosis in patients with chondrosarcoma, Ewing’s sarcoma and osteosarcoma. Current concepts. J. Biol. Regul. Homeost. Agents 2019 33 2 39 43 31169001
    [Google Scholar]
  27. Jiang J. Liu C. Xu G. Liang T. Yu C. Liao S. Zhang Z. Lu Z. Wang Z. Chen J. Chen T. Li H. Zhan X. CCT6A, a novel prognostic biomarker for Ewing sarcoma. Medicine (Baltimore) 2021 100 4 e24484 10.1097/MD.0000000000024484 33530265
    [Google Scholar]
  28. Suehara Y. Tochigi N. Kubota D. Kikuta K. Nakayama R. Seki K. Yoshida A. Ichikawa H. Hasegawa T. Kaneko K. Chuman H. Beppu Y. Kawai A. Kondo T. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J. Proteomics 2011 74 6 829 842 10.1016/j.jprot.2011.02.033 21385630
    [Google Scholar]
  29. Strasser A. Wittmann H.J. Seifert R. Binding kinetics and pathways of ligands to GPCRs. Trends Pharmacol. Sci. 2017 38 8 717 732 10.1016/j.tips.2017.05.005 28645833
    [Google Scholar]
  30. Chan H.C.S. Wang J. Palczewski K. Filipek S. Vogel H. Liu Z.J. Yuan S. Exploring a new ligand binding site of G protein-coupled receptors. Chem. Sci. (Camb.) 2018 9 31 6480 6489 10.1039/C8SC01680A 30310578
    [Google Scholar]
  31. Briukhovetska D. Dörr J. Endres S. Libby P. Dinarello C.A. Kobold S. Interleukins in cancer: From biology to therapy. Nat. Rev. Cancer 2021 21 8 481 499 10.1038/s41568‑021‑00363‑z 34083781
    [Google Scholar]
  32. Chandan N.R. Abraham S. SenGupta S. Parent C.A. Smrcka A.V. A network of Gα i signaling partners is revealed by proximity labeling proteomics analysis and includes PDZ-RhoGEF. Sci. Signal. 2022 15 717 eabi9869 10.1126/scisignal.abi9869 35041463
    [Google Scholar]
  33. Yang D. Zhou Q. Labroska V. Qin S. Darbalaei S. Wu Y. Yuliantie E. Xie L. Tao H. Cheng J. Liu Q. Zhao S. Shui W. Jiang Y. Wang M.W. G protein-coupled receptors: Structure- and function-based drug discovery. Signal Transduct. Target. Ther. 2021 6 1 7 10.1038/s41392‑020‑00435‑w 33414387
    [Google Scholar]
  34. Spangler J.B. Moraga I. Mendoza J.L. Garcia K.C. Insights into cytokine-receptor interactions from cytokine engineering. Annu. Rev. Immunol. 2015 33 1 139 167 10.1146/annurev‑immunol‑032713‑120211 25493332
    [Google Scholar]
  35. Labelle M. Begum S. Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011 20 5 576 590 10.1016/j.ccr.2011.09.009 22094253
    [Google Scholar]
  36. Shitara K. Ueha S. Shichino S. Aoki H. Ogiwara H. Nakatsura T. Suzuki T. Shimomura M. Yoshikawa T. Shoda K. Kitano S. Yamashita M. Nakayama T. Sato A. Kuroda S. Wakabayashi M. Nomura S. Yokochi S. Ito S. Matsushima K. Doi T. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. J. Immunother. Cancer 2019 7 1 195 10.1186/s40425‑019‑0677‑y 31340866
    [Google Scholar]
  37. Pandolfi F. Franza L. Todi L. Carusi V. Centrone M. Buonomo A. Chini R. Newton E.E. Schiavino D. Nucera E. The importance of complying with vaccination protocols in developed countries: “Anti-Vax” Hysteria and the spread of severe preventable diseases. Curr. Med. Chem. 2019 25 42 6070 6081 10.2174/0929867325666180518072730 29773050
    [Google Scholar]
  38. Yokoi K. Nakajima Y. Matsuoka H. Shinkai Y. Ishihara T. Maeda Y. Kato T. Katsuno H. Masumori K. Kawada K. Yoshikawa T. Ito T. Kurahashi H. Impact of DPYD, DPYS, and UPB1 gene variations on severe drug‐related toxicity in patients with cancer. Cancer Sci. 2020 111 9 3359 3366 10.1111/cas.14553 32619063
    [Google Scholar]
/content/journals/cpps/10.2174/0113892037362065250227064739
Loading
Unveiling the Role of DPYS: A New Prognostic Biomarker in Sarcoma
Bentham Science Publishers ; https://doi.org/10.2174/0113892037362065250227064739
/content/journals/cpps/10.2174/0113892037362065250227064739
/content/journals/cpps/10.2174/0113892037362065250227064739
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: prognosis ; Sarcoma ; therapeutic target ; immune infiltrates ; GPCR ligand binding ; dihydropyrimidinase

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test